Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer (Version 5.2021). National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed September 24, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for the application or use in any way.
ASCO = American Society of Clinical Oncology; HER = human epidermal growth factor receptor; MBC = metastatic breast cancer; NCCN = National Comprehensive Cancer Network.
References: 1. Brufsky AM, Mayer M, Rugo HS, et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin Cancer Res. 2011;17(14):4834-4843. 2. Niwińska A, Tacikowska M, Murawska M. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys. 2010;77(4):1134-1139. 3. Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO clinical practice guideline update. J Clin Oncol. 2018;36(27):2804-2807. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Breast Cancer V.8.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed September 24, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 5. Irvin W Jr, Muss HB, Mayer DK. Symptom management in metastatic breast cancer. Oncologist. 2011;16(9):1203-1214. 6. Oltean D, Dicu T, Eniu D. Brain metastases secondary to breast cancer: symptoms, prognosis and evolution. Tumori. 2009;95(6):697-701. 7. Cacho-Díaz B, Spínola-Maroño H, Arrieta VA, et al. Diagnosis of brain metastases in breast cancer patients resulting from neurological symptoms. Clin Neurol Neurosurg. 2018;173:61-64. 8. von Minckwitz G, Huang C-S, Mano MS, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617-628. 9. Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724-734. 10. Docetaxel [Prescribing Information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC. May 2010. 11. Paclitaxel [Prescribing Information]. Princeton, NJ: Bristol-Myers Squibb Company. April 2011. 12. Capecitabine [Prescribing Information]. South San Francisco, CA: Genentech USA, Inc. May 2021. 13. American College of Emergency Physicians. Clinical policy for the initial approach to patients presenting with altered mental status. Ann Emerg Med. 1999;33(2):251-281.